Table 2.

Change in serum phosphorus from baseline to end of stage 1 in the sucroferric oxyhydroxide group (FAS and PPS populations)

Parameter	FAS population (n = 65)	PPS population (n = 42)
Baseline
Mean ± SD, mg/dL	6.45 ± 1.698	6.31 ± 1.605
End of stage 1
Mean ± SD, mg/dL	5.90 ± 1.990	5.68 ± 2.106
Change from BL to end of stage 1
Mean ± SD	− 0.54 ± 1.508	− 0.63 ± 1.675
Pre-defined modela
LS mean ± SE	− 0.371 ± 0.251	− 0.433 ± 0.388
95% CI	− 0.874, 0.132	− 1.220, 0.353
p valueb	0.146	0.271
Post hoc modelc
LS mean ± SE   95% CI   p valueb	− 0.488 ± 0.186 − 0.861, − 0.116 0.011	− 0.552 ± 0.270 − 1.098, − 0.005 0.048

BL, baseline; CI, confidence interval; FAS, full analysis set; LS, least squares; PPS, per protocol set; SD, standard deviation; SE, standard error

^aResults are obtained from a linear mixed model that includes change in serum phosphorus levels from baseline to the end of stage 1 as dependent variable and treatment, baseline serum phosphorus, age (in categories) at randomization, region (non-US/US), and gender as fixed effects (pre-defined statistical model)

^bp value for least squares means t test is presented

^cResults are obtained from a linear mixed model which includes change in serum phosphorus levels from baseline to the end of stage 1 as dependent variable and treatment, baseline serum phosphorus, age at randomization, region (non-US/US), and gender as fixed effects (post hoc analysis)